Oncology Drugs Global Market Report 2018

1. Oncology Drugs Global Market Report 2018 Including: Blood Cancer; Breast Cancer; Cervical Cancer; Lung Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer; Prostate Cancer; Kidney Cancer; Pancreatic Cancer; Brain Tumor; Gastric Cancer; Skin Cancer; Ovarian Cancer; Bladder Cancer; Thyroid Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma) Covering: F. Hoffmann-La Roche Ltd, Novartis AG, Gilead Sciences Inc., Bayer AG, Takeda Pharmaceuticals Feb 2018

2. Reasons to Purchase • Outperform competitors using accurate up to date demand-side dynamics information. • Identify growth segments for investment. • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market. • Create regional and country strategies on the basis of local data and analysis. • Stay abreast of the latest customer and market research findings • Benchmark performance against key competitors. • Develop strategies based on likely future developments. • Utilize the relationships between key data sets for superior strategizing. • Suitable for supporting your internal and external presentations with reliable high quality data and analysis • Gain a global perspective on the development of the market. • Report will be updated with the latest data and delivered to you within 3-5 working days of order. Scope Markets Covered: Blood Cancer; Breast Cancer; Cervical Cancer; Lung Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer; Prostate Cancer; Kidney Cancer; Pancreatic Cancer; Brain Tumor; Gastric Cancer; Skin Cancer; Ovarian Cancer; Bladder Cancer; Thyroid Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma) Companies Mentioned: F. Hoffmann-La Roche Ltd, Novartis AG, Gilead Sciences Inc., Bayer AG, Takeda Pharmaceuticals Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia. Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast. Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, Oncology Drugs Market Indicators Comparison. Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments. Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

3. Oncology Drugs Oncology Drugs Market Characteristics Characteristics Market Oncology deals with diagnosis, prevention and treatment of cancer diseases. Anti- cancer or anti-neoplastic agents are the drugs that prevent or inhibit or halt the proliferation and maturation of neoplasms, an abnormal growth of tissues commonly referred as tumors. These drugs prevent the growth of malignant tumors by affecting the process of cell division or by damaging the DNA and initiate apoptosis or by preventing the development and spread of neoplastic cells. Several types of cancers that can be treated by oncology drugs are blood cancer, lung cancer, endocrine cancer, bone cancer, gastric cancer, colorectal cancer, skin cancer, breast cancer, pancreatic cancer, prostate cancers, ovarian cancer, ocular cancer and others. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing. Based on the type and stage of cancer, treatment options include Surgery, Radiation therapy, chemotherapy, immunotherapy, targeted therapy, hormone therapy, and stem cell transplant. In most cases, a combination of more than one type of treatment is chosen. Treatment with drugs include the following categories – Chemotherapy Drugs –are the medications used for cancer treatment. They function by inhibiting cell division or Immunotherapy Or Biologic Therapy Or Biotherapy Drugs – Targeted Therapy Drugs – Hormone Therapy – Stem Cell Transplants –

4. The oncology drugs market data is segmented based on the actual usage for diseases, as follows: • Blood Cancer Drugs • Breast Cancer Drugs • Cervical Cancer Drugs • Lung Cancer Drugs • Colorectal Cancer Drugs • Non-Small Cell Lung Cancer Drugs • Prostate Cancer Drugs • Kidney Cancer Drugs • Gastric Cancer Drugs • Brain Tumor Drugs • Pancreatic Cancer Drugs • Skin Cancer Drugs • Ovarian Cancer Drugs • Bladder Cancer Drugs • Thyroid Cancer Drugs • Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma) However, some of the drugs are used for one or more types of cancers. In this report market value is defined as the revenues organizations earn by selling their goods and services within the specified market, based on the price at which they sell. Only goods and services traded between entities are included. The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.

5. Oncology Drugs Oncology Drugs Market Market Historic Historic Growth Growth The global oncology drugs market grew from $X billion in 2013 to $X billion in 2017 at a compound annual growth rate (CAGR) of X%. The chart and table below shows the year-on-year growth of the global oncology drugs market during 2013 – 2017. Drivers of the Market: Restraints on the Market:

6. Oncology Drugs Oncology Drugs Market Market Forecast Forecast Growth Growth The global Oncology Drugs market grew from $XX billion in 2017 to $165.00 billion in 2021 at a compound annual growth rate (CAGR) of XX%. The oncology drugs market is expected to grow due to the increasing number of expensive but advanced and effective medications that will help in increasing the life expectancy of cancer patients. For example, in 2017, Kite Pharma’s CAT-T cell therapy, under clinical trial, showed results of The chart and table below shows the year-on-year growth of the global oncology drugs market during 2017 - 2021. Drivers of the Market: Restraints on the Market:

7. Oncology Drugs Oncology Drugs Market Segmentation Segmentation Market The chart and table below shows the split of the oncology drugs market in 2017. *Others include Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma. The total market value for oncology drugs was $X billion in 2017. The markets that are covered include Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Kidney Cancer, Gastric Cancer, Brain Tumor, Pancreatic Cancer, Skin Cancer, Ovarian Cancer, Bladder Cancer, Thyroid Cancer, and Others. Blood Cancer Drugs was the x largest segment in the oncology drugs market with X% share of the market. The market value for the blood cancer was $x billion in 2017. Breast Cancer Drugs made up around X% share of the market. The market value for the breast cancer drugs was $x billion in 2017.

8. Oncology Drugs Oncology Drugs Market And Country Analysis And Country Analysis Market Regional Regional The Asia Pacific was the x largest region in the oncology drugs market in 2017, oncology drugs for $X billion or X% market share. North America was the x largest region oncology drugs for $X billion or X% market share. Europe was the x largest region oncology drugs for $X billion or X% market share.

9. Oncology Drugs Oncology Drugs Market Competitive Landscape Competitive Landscape Market The leading competitors in the global oncology drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, Gilead Sciences Inc., Bayer AG, Takeda Pharmaceuticals. The chart and table below displays the percentage market share of the top players in the oncology drugs market industry. F. Hoffmann-La Roche Ltd. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Novartis AG generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Gilead Sciences, Inc. generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Bayer AG generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Takeda Pharmaceuticals generated revenues of $XX billion for the financial year 2015, an XX% increase from the previous year.

10. Johnson & Johnson generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Pfizer Inc. generated revenues of $XX billion for the financial year 2016, an 5XX% increase from the previous year. Boehringer Ingelheim GmbH generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Eli Lilly And Company generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Otsuka Pharmaceutical Co., Ltd. generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Company Profile F.Hoffmann-La Roche Overview Roche was the X largest competitor in the oncology drugs market in 2017 with XX% share of the market. It is a multinational healthcare company that focuses on developing medicines and diagnostics. The company was founded in 1896 and is headquartered in Basel, Switzerland. Products and Services The company operates through the following divisions – The Pharmaceutical division develops, The Diagnostics division manufactures Strategy Roche’s growth strategy aims at increasing revenues from its laboratory business by introducing new medicines into the market. In 2016, the company launched four new medicines

11. Financial Performance F.Hoffmann-La Roche’s Pharmaceutical division, involved in oncology drugs manufacturing, generated revenues of CHF XX billion ($XX billion) for the financial year 2016, a XX% increase from the previous year. The company had a market Novartis Overview Products and Services Strategy Financial Performance Gilead Sciences, Inc. Overview Products and Services Strategy Financial Performance Bayer AG Overview Products and Services Strategy Financial Performance

12. Takeda Pharmaceuticals Overview Products and Services Strategy Financial Performance